Coversin - Akari Therapeutics

Drug Profile

Coversin - Akari Therapeutics

Alternative Names: Coversin; EV 576; PAS-coversin; rEV 576

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Guillain-Barre syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Bullous pemphigoid; Conjunctivitis; Myasthenia gravis; Sjogren's syndrome
  • No development reported Guillain-Barre syndrome
  • Discontinued Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 21 Mar 2018 Akari Therapeutics receives regulatory approval to initiate phase III CAPSTONE trial in Paroxysmal nocturnal haemoglobinuria in Europe
  • 07 Feb 2018 Akari Therapeutics completes the phase II COBALT trial in Paroxysmal nocturnal haemoglobinuria in United Kingdom (SC)
  • 06 Feb 2018 Akari Therapeutics plans a phase II trial for Bullous Pemphigoid in first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top